TY  - JOUR
SN  - 1468-1331
N2  - The use of carbamazepine (CBZ) and oxcarbazepine (OXC) as first-line antiepileptic drugs in the treatment of focal epilepsy is limited by hyponatremia, a known adverse effect. Hyponatremia occurs in up to half of people taking CBZ or OXC and, although often assumed to be asymptomatic, it can lead to symptoms ranging from unsteadiness and mild confusion to seizures and coma. Hyponatremia is probably due to the antidiuretic properties of CBZ and OXC that are, at least partly, explained by stimulation of the vasopressin 2 receptor/aquaporin 2 pathway. No known genetic risk variants for CBZ- and OXC-induced hyponatremia exist, but likely candidate genes are part of the vasopressin water reabsorption pathway.
SP  - 1393
AV  - public
ID  - discovery1504767
UR  - http://dx.doi.org/10.1111/ene.13069
N1  - Copyright © 2016 EAN. This is the peer reviewed version of the following article: [Berghuis, B., de Haan, G.-J., van den Broek, M. P. H., Sander, J. W., Lindhout, D. and Koeleman, B. P. C. (2016), Epidemiology, pathophysiology and putative genetic basis of carbamazepine- and oxcarbazepine-induced hyponatremia. European Journal of Neurology, 23: 1393?1399. doi: 10.1111/ene.13069], which has been published in final form at http://dx.doi.org/10.1111/ene.13069. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
JF  - European Journal of Neurology
A1  - Berghuis, B
A1  - de Haan, GJ
A1  - van den Broek, MP
A1  - Sander, JW
A1  - Lindhout, D
A1  - Koeleman, BP
KW  - antiepileptic drugs
KW  -  drug treatment
KW  -  epilepsy
KW  -  sodium
KW  -  vasopressin receptor 2
EP  - 1399
IS  - 9
Y1  - 2016/09//
TI  - Epidemiology, pathophysiology and putative genetic basis of carbamazepine- and oxcarbazepine-induced hyponatremia
VL  - 23
ER  -